WallStSmart

VectivBio Holding AG (VECT)vsMeridian Bioscience Inc (VIVO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Meridian Bioscience Inc generates 1118% more annual revenue ($333.02M vs $27.34M). VIVO leads profitability with a 12.8% profit margin vs 0.0%. VIVO earns a higher WallStSmart Score of 48/100 (D+).

VECT

Avoid

25

out of 100

Grade: F

Growth: 4.3Profit: 2.5Value: 5.0Quality: 8.5
Piotroski: 4/9Altman Z: 2.13

VIVO

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 7.0Value: 8.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for VECT.

VIVOSignificantly Overvalued (N/A)

Margin of Safety

N/A

Fair Value

$6.53

Current Price

$2.24

$4.29 premium

UndervaluedFair: $6.53Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

VECT1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

VIVO2 strengths · Avg: 9.0/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Operating MarginProfitability
22.7%8/10

Strong operational efficiency at 22.7%

Areas to Watch

VECT4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.06B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

VIVO4 concerns · Avg: 2.8/10
P/E RatioValuation
35.4x4/10

Premium valuation, high expectations priced in

Market CapQuality
$1.49B3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-13.8%2/10

Revenue declined 13.8%

EPS GrowthGrowth
-13.0%2/10

Earnings declined 13.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : VECT

The strongest argument for VECT centers on Debt/Equity.

Bull Case : VIVO

The strongest argument for VIVO centers on Price/Book, Operating Margin. PEG of 1.33 suggests the stock is reasonably priced for its growth.

Bear Case : VECT

The primary concerns for VECT are Revenue Growth, EPS Growth, Market Cap.

Bear Case : VIVO

The primary concerns for VIVO are P/E Ratio, Market Cap, Revenue Growth.

Key Dynamics to Monitor

VECT profiles as a value stock while VIVO is a declining play — different risk/reward profiles.

VIVO carries more volatility with a beta of 0.23 — expect wider price swings.

VECT is growing revenue faster at 0.0% — sustainability is the question.

VECT generates stronger free cash flow (54M), providing more financial flexibility.

Bottom Line

VIVO scores higher overall (48/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

VectivBio Holding AG

HEALTHCARE · PHARMACEUTICALS · USA

VectivBio Holding AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of treatments for rare conditions. The company is headquartered in Basel, Switzerland.

Visit Website →

Meridian Bioscience Inc

HEALTHCARE · PHARMACEUTICALS · USA

Meridian Bioscience, Inc., a life sciences company, develops, manufactures, distributes and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases and elevated blood lead levels worldwide. The company is headquartered in Cincinnati, Ohio.

Want to dig deeper into these stocks?